JS
JSS.F Sosei Group Corporation
- Market cap
- EUR 926M
- P/E
- -
- P/B
- 2.55x
- ROE
- 4.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is JSS.F undervalued?
Graham numberThe Graham number of Sosei Group Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sosei Group Corporation fundamental analysis
No fundamental analysis for Sosei Group Corporation yet.
Sosei Group Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sosei Group Corporation
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 ago…
Full company profileSosei Group Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sosei Group Corporation annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.9B | 6.96B | - | 9.73B | 8.84B | 17.7B | 15.6B | 12.8B | 28.8B | 29.6B | 37.0B |
| Gross Profit | 18.9B | 6.96B | - | 8.88B | 8.08B | 16.8B | 14.6B | 9.66B | 21.2B | 21.4B | 31.3B |
| Operating Income | 12.4B | -2.29B | - | 384M | 928M | 3.78B | 3.44B | -9.53B | -5.42B | -8.46B | 4.23B |
| EBITDA | - | -1.44B | - | 2.52B | 3.55B | 5.51B | 3.18B | -5.71B | 105M | -3.11B | 8.88B |
| Net Income | 9.64B | -2.65B | - | 1.43B | 1.48B | 1.02B | 382M | -7.19B | -4.84B | -12.5B | 3.10B |
| EPS | 142 | -35 | - | 19 | 18 | 12 | 4.66 | -80 | -54 | -138 | 34 |
| Balance Sheet | |||||||||||
| Total Assets | 48.1B | 69.5B | - | 56.7B | 76.5B | 97.0B | 99.4B | 157B | 151B | 135B | 130B |
| Total Liabilities | 19.2B | 20.6B | - | 11.6B | 24.1B | 39.5B | 41.5B | 90.4B | 83.0B | 73.8B | 66.1B |
| Shareholders' Equity | 28.8B | 48.9B | - | 45.1B | 52.4B | 57.5B | 57.9B | 66.8B | 68.5B | 61.0B | 64.2B |
| Cash & Short-term Investments | 13.9B | 28.3B | - | 15.4B | 40.0B | 60.1B | 66.6B | 49.1B | 32.3B | 20.4B | 16.6B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.9B | -2.17B | -6.05B | 3.44B | 4.67B | 7.10B | 9.95B | 653M | -7.72B | -2.67B | 7.64B |
| Capital Expenditure | 332M | 880M | 2.23B | 271M | 92.0M | 193M | 277M | 615M | 1.54B | 625M | 7.57B |
| Free Cash Flow | - | -3.05B | - | 3.16B | 4.57B | 6.89B | 9.65B | 38.0M | -9.26B | -3.29B | 65.3M |
| Ratios | |||||||||||
| ROE | 33.4% | -5.4% | - | 3.2% | 2.8% | 1.8% | 0.7% | -10.8% | -7.1% | -20.5% | 4.8% |
| ROA | 20.0% | -3.8% | - | 2.5% | 1.9% | 1.0% | 0.4% | -4.6% | -3.2% | -9.3% | 2.4% |
| Net Profit Margin | 51.0% | -38.2% | - | 14.7% | 16.7% | 5.7% | 2.5% | -56.3% | -16.8% | -42.3% | 8.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sosei Group Corporation dividends
Sosei Group Corporation has not paid dividends in the last 9 fiscal years.
Who owns Sosei Group Corporation
- Insiders 18.19%
- Institutions 33.34%
- Public & others 48.48%
- Shares outstanding 91.7M
- Free float 75.5M
Sosei Group Corporation company profile
- Company name
- Sosei Group Corporation
- Ticker
- JSS.F
- ISIN
- JP3431300007
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 314
- Fiscal year end
- December
- Address
- Midtown East, Minato, Japan, 107-0052
- Phone
- 81 3 5962 5718
- Website
- nxera.life
About Sosei Group Corporation
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company's products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan.
Sosei Group Corporation management
10- Mr. Christopher CargillRepresentative Executive Officer, President, CEO & Chairman · born 1984
- Mr. Hironoshin NomuraExecutive Officer & CFO · born 1983
- Dr. Shinichi TamuraFounder · born 1949
- Mr. Toshihiro MaedaPresident of Nxera Pharma Japan & COO · born 1979
- Mr. Kieran Johnson F.C.A.Executive Officer & Chief Accounting Officer · born 1969
- Dr. Patrik Foerch Ph.D.Chief Scientific Officer, President of Nxera Pharma UK & Director
- Mr. Shinya TsuzukiHead of Investor Relations · born 1993
- Ms. Mariko NakafujiExecutive VP & Chief Legal Officer
- Mr. Shinichiro NishishitaVP of Investor Relations & Head of Regulatory Disclosures
- Stacey SouthallAssociate Director & Head of Biophysics